Tirosint Medicare Part D Coverage: How to Get Levothyroxine Gel Caps Covered

Why Tirosint Costs More Than Standard Levothyroxine Tablets

Tirosint is a brand-name, liquid-filled gel capsule formulation of levothyroxine sodium manufactured by IBSA Pharma. Its cash price sits near $230 for 30 capsules. Generic levothyroxine tablets, by comparison, cost $4 to $15 at most pharmacies.

The price gap exists because Tirosint contains only three inactive ingredients (gelatin, glycerin, and water), while standard levothyroxine tablets contain dyes, fillers, lactose, gluten, and other excipients that can interfere with absorption in certain patients. A 2015 study published in Endocrine Practice found that patients with GI malabsorption conditions, including celiac disease, lactose intolerance, and gastric bypass history, achieved more consistent TSH levels after switching from tablet levothyroxine to liquid or gel cap formulations [1]. The American Thyroid Association (ATA) 2014 guidelines for hypothyroidism management note that liquid or softgel levothyroxine preparations may benefit patients who cannot achieve stable TSH despite adherence to tablet therapy [2].

That clinical profile makes Tirosint medically necessary for a specific subset of hypothyroid patients. But the $230 retail price means coverage strategy matters enormously.

How Medicare Part D Plans Classify Tirosint

Tirosint appears on the majority of Medicare Part D formularies, but its tier placement varies significantly by plan. Most plans slot it at Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with corresponding copays between $40 and $95 per fill during the initial coverage phase.

A smaller number of plans exclude Tirosint entirely, requiring a formulary exception request. To determine your specific plan's coverage, search the Medicare Plan Finder at medicare.gov using the drug name and your zip code. Each plan's formulary is updated quarterly, so verifying before each enrollment period is necessary.

During the initial coverage phase in 2026, Part D enrollees pay their plan's listed copay until combined spending (patient plus plan) reaches $5,550. After that, the catastrophic phase begins, where out-of-pocket costs drop to 5% coinsurance or a small copay. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective in 2025, means no Medicare Part D enrollee pays more than $2,000 total per year across all covered prescriptions [3]. For patients on Tirosint plus other brand medications, that cap provides real relief.

Prior Authorization and Step Therapy Requirements

Approximately 35% of Medicare Part D plans require prior authorization (PA) before covering Tirosint. An even larger share impose step therapy, meaning your prescriber must document that you tried and failed generic levothyroxine tablets first.

The PA process typically requires your physician to submit documentation showing at least one of the following: erratic TSH levels despite adherence to generic tablets, a diagnosed malabsorption condition (celiac disease, inflammatory bowel disease, short bowel syndrome, post-bariatric surgery), documented allergy or sensitivity to dyes, lactose, or other tablet excipients, or concomitant use of a proton pump inhibitor (PPI) that impairs tablet absorption.

A 2017 retrospective analysis in Thyroid (N=99) demonstrated that patients switched from levothyroxine tablets to Tirosint while on concomitant PPI therapy showed a 29% reduction in mean TSH within 8 weeks without dose adjustment [4]. This type of evidence strengthens a PA appeal.

If your plan denies coverage, you have the right to request a coverage determination and, if denied again, a formal appeal. Medicare requires Part D plans to respond to standard requests within 72 hours and expedited requests within 24 hours. The Centers for Medicare & Medicaid Services (CMS) publishes appeal instructions at cms.gov.

The Coverage Gap and the $2,000 Out-of-Pocket Cap

The old Medicare "donut hole" created a painful cost spike for brand-name medications. Under the Inflation Reduction Act signed in 2022, the Part D benefit was restructured with a hard $2,000 annual out-of-pocket maximum starting January 2025 [3].

Here is what that means in practice for Tirosint users. If your copay is $75 per month, you would hit the $2,000 cap by roughly month 27 of continuous fills in a single calendar year, so most patients on Tirosint alone will not reach the cap from that single medication. But if you take other brand-name drugs (a common scenario for patients with thyroid disease who also manage cardiovascular or metabolic conditions), the combined out-of-pocket spending counts toward the cap. Once you cross $2,000, you pay $0 for the rest of the plan year.

CMS also expanded the Medicare Part D Low Income Subsidy (LIS, also called "Extra Help") in 2024. Beneficiaries earning below 150% of the federal poverty level ($23,895 for an individual in 2026) qualify for copays capped at $4.50 for generics and $11.20 for brand drugs per fill [5]. For Tirosint, that drops a $75 copay to $11.20. Apply through the Social Security Administration at ssa.gov.

IBSA's Manufacturer Savings Program

IBSA Pharma offers a Tirosint Savings Card that can reduce copays to as low as $25 for eligible commercially insured patients. The card covers up to a maximum annual benefit amount.

There is a hard limit. Federal law (the Anti-Kickback Statute) prohibits manufacturer copay cards from being used by Medicare, Medicaid, or other federally funded insurance beneficiaries [6]. Medicare Part D enrollees cannot use the IBSA savings card. This restriction also applies to Medicare Advantage plans with Part D (MA-PD plans) and Tricare.

For Medicare patients seeking additional financial help, alternative pathways include the following.

Patient Assistance Programs (PAPs). IBSA does not currently operate a standalone PAP for Medicare patients, but the situation changes periodically. Contact IBSA directly at their patient support number listed on tirosint.com to verify current offerings.

State Pharmaceutical Assistance Programs (SPAPs). About 20 states run SPAPs that supplement Medicare Part D coverage. These programs may cover part or all of the copay for Tirosint. A full list is maintained by the Medicare Rights Center.

Nonprofit copay foundations. Organizations like the PAN Foundation, HealthWell Foundation, and NeedyMeds periodically open thyroid-specific funds. Funding cycles are unpredictable, with some funds opening and closing within days. Set up alerts at needymeds.org.

Switching Plans During Open Enrollment

The most effective long-term cost strategy for Medicare beneficiaries on Tirosint is plan selection during the Annual Enrollment Period (AEP), which runs October 15 through December 7 each year.

Not all Part D plans are equal for Tirosint coverage. The difference between a plan that lists Tirosint at Tier 3 with a $42 copay and one that lists it at Tier 4 with a $95 copay amounts to over $630 per year. Some plans also waive prior authorization for Tirosint, which eliminates the administrative burden entirely.

Use the Medicare Plan Finder tool to compare formulary tier, copay amount, prior authorization requirements, and step therapy rules across all plans available in your zip code. Enter Tirosint specifically (not generic levothyroxine) because the two have different tier placements. A 2022 JAMA Internal Medicine study analyzing Medicare Part D formulary data found that the same brand-name drug could vary by more than $1,200 in annual out-of-pocket cost across plans in the same geographic region [7].

If you receive care from a specific pharmacy or prefer mail-order, confirm that your chosen pharmacy is in-network for the plan. Preferred pharmacy networks can reduce copays by 15% to 30%.

When Generic Levothyroxine Tablets Are the Right Choice

Tirosint is not necessary for every hypothyroid patient. The ATA guidelines state that standard levothyroxine tablets are appropriate first-line therapy for the vast majority of hypothyroid patients [2]. TSH stability on tablets, absence of malabsorption conditions, and tolerance of tablet excipients all point toward staying on generic.

Generic levothyroxine tablets (manufactured by Mylan, Lannett, Sandoz, and others) cost $4 to $15 per month at retail and are listed on Tier 1 (preferred generic) of nearly every Part D plan, often with copays of $0 to $10.

Dr. Victor Bernet, past president of the American Thyroid Association, has noted: "For most patients with hypothyroidism, generic levothyroxine provides reliable TSH control. The gel cap and liquid formulations fill a real need, but that need is confined to patients with documented absorption issues or excipient sensitivities" [8].

Switching from Tirosint to a generic tablet could save a Medicare patient $400 to $1,000 annually in copays. However, thyroid hormone replacement is narrow therapeutic index (NTI), meaning small absorption differences can produce clinically significant TSH changes. The FDA requires that generic levothyroxine products demonstrate bioequivalence within a 90% to 111% confidence interval for AUC and Cmax [9]. If you switch, your physician should recheck TSH in 6 to 8 weeks.

Compounded Levothyroxine: A Niche Alternative

Some compounding pharmacies prepare liquid levothyroxine for patients who cannot swallow capsules or tablets. Compounded drugs are not FDA-approved, carry no FDA bioequivalence requirement, and are not standardized across pharmacies.

Medicare Part D generally does not cover compounded medications unless they contain at least one FDA-approved active ingredient and are prepared by a pharmacy that meets section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. In practice, most Part D plans exclude compounded thyroid preparations from formulary coverage.

The Endocrine Society's 2012 clinical practice guideline on hypothyroidism explicitly recommends against compounded thyroid preparations due to inconsistent potency and lack of regulatory oversight [10]. For patients who genuinely cannot use tablets or gel caps, discussion with an endocrinologist about Tirosint SOL (the liquid solution formulation, also by IBSA) may be a better regulated option.

Tirosint SOL: The Liquid Alternative

IBSA also manufactures Tirosint-SOL, an oral liquid solution of levothyroxine in unit-dose ampules. It is bioequivalent to Tirosint gel caps and carries the same clinical advantages for malabsorption patients.

Tirosint-SOL's Medicare Part D coverage status mirrors that of the gel cap: most plans cover it on Tier 3 or Tier 4 with similar copays. Some plans cover one formulation but not the other, so if you are denied for the gel cap, asking about the liquid solution (and vice versa) is worth exploring.

The oral solution is administered by squeezing the ampule directly into the mouth or into a small amount of water. No food interaction waiting period differs from the gel cap. Both require a 30- to 60-minute fasting window before eating for optimal absorption, consistent with all levothyroxine formulations [2].

Step-by-Step: Getting Tirosint Covered Under Your Part D Plan

The process follows a predictable sequence that your prescriber's office can manage alongside your pharmacy.

First, confirm your plan's formulary status. Log into your Part D plan's member portal or call the number on the back of your card. Ask specifically whether Tirosint is covered, which tier it occupies, and whether PA or step therapy applies.

Second, if step therapy is required, ensure your medical records document prior use of generic levothyroxine tablets. If you tried tablets through a previous provider, request those records be forwarded.

Third, if PA is required, your prescriber submits clinical justification. Include diagnosis codes (E03.9 for hypothyroidism), documentation of malabsorption or excipient sensitivity, TSH lab trends showing instability on tablets, and any supporting GI diagnoses.

Fourth, if denied, file an appeal within 60 days. Include a letter of medical necessity from your physician citing the ATA guidelines and any relevant absorption studies. The CMS data shows that approximately 55% of Part D coverage determination appeals are decided in the beneficiary's favor [11].

Fifth, if the appeal fails, consider switching Part D plans during AEP. A plan that covers Tirosint without PA at a lower tier may be available in your area.